Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 2/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 2/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 2/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 2/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 2/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 2/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 1.00 |
| ▸ | GABRD | O14764 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 1/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 1/20 | 1.00 |
| ▸ | GABRE | P78334 | 1/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 1/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 1/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 13/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | BRD2 | P25440 | 1/20 | 0.56 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835654 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2929181 | 1.00 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9866516 | 0.90 | GABRP (0.82) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9432239 | 0.90 | GABRP (0.82) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9432242 | 0.90 | GABRP (0.82) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9432235 | 0.90 | GABRP (0.82) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9866526 | 0.90 | GABRP (0.82) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9866520 | 0.90 | GABRP (0.82) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3286663 | 0.89 | GABRP (0.80) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3287270 | 0.89 | GABRP (0.80) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | claimed |
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-08-28 | — | — | US | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | claimed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | claimed |
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006071775-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| EP-1633348-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | claimed |
| CN-1399634-A | Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB PHARMA IN (US) | 2003-02-26 | — | — | CN | claimed |
| US-6503901-B1 | Alzheimer*s disease and Down*s syndrome treatment | BRISTOL MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | claimed |
| EP-1218377-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2002-07-03 | — | — | EP | claimed |
| WO-2001027108-A1 | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| EP-0167919-B1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1993-05-05 | — | — | EP | claimed |
| EP-0253571-B1 | PROCESS FOR RESOLUTION AND RACE MIZATION OF AMINES WITH ACIDIC ALPHA-HYDROGENS | MERCK & CO. INC. (US) | 1989-08-23 | — | — | EP | claimed |
| US-4859771-A | Process for resolution and racemization of amines with acidic α-hydrogens | MERCK & CO., INC. (US) | 1989-08-22 | — | — | US | claimed |
| EP-0253571-A1 | Process for resolution and race mization of amines with acidic alpha-hydrogens | MERCK & CO. INC. (US) | 1988-01-20 | — | — | EP | claimed |
| EP-0167919-A2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-01-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | GABRA1 194/4885GABRG2 491/4885GABRB3 242/4885 |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, GABRE | GABRA1 8/4885GABRG2 25/4885GABRB3 11/4885 |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | APP, APH1A, BACE1 | GABRA1 1484/4885GABRG2 1917/4885GABRB3 1480/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | GABRA1 211/4885GABRG2 626/4885GABRB3 271/4885 |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | GABRA1 41/4885GABRG2 208/4885GABRB3 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.